Hezel, A F
Noel, M S
Allen, J N
Abrams, T A
Yurgelun, M
Faris, J E
Goyal, L
Clark, J W
Blaszkowsky, L S
Murphy, J E
Zheng, H
Khorana, A A
Connolly, G C
Hyrien, O
Baran, A
Herr, M
Ng, K
Sheehan, S
Harris, D J
Regan, E
Borger, D R
Iafrate, A J
Fuchs, C
Ryan, D P
Zhu, A X
Article History
Received: 30 January 2014
Revised: 30 April 2014
Accepted: 12 May 2014
First Online: 24 June 2014
Competing interests
: AFH has served as a consultant to Bayer and Novartis and has received speaking honoraria from Celgene, Bayer, and Novartis. MSN has served as a consultant for Bayer. DRB is a consultant for Bio-Reference Laboratories. CF has served as a consultant for Amgen, Takeda, Metamark, Genetics, Genentech, Acceleron and Momenta Pharmaceuticals. AXZ has served as a consultant for Acceleron Pharmaceuticals, Sanofi-aventis, Exelixis, Daiichi Sankyo, Eisai, Celgene and Jennerex. The remaining authors declare no conflict of interest.